Paradigm Biopharmaceuticals Receives Ethics Approval
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- Paradigm starts Clinical Trial
- Paradigm initiates second clinical trial site
- First Participant treated in Paradigms Clinical Trial
- European Patent Office Grants PAR Key Respiratory Patent
- Elite Athlete successfully treated with Paradigms Zilosul
Later from Paradigm Biopharmaceuticals
- ASX Admission Market Release
- Shareholders Update
- Paradigm PPS nasal spray to treat Allergic Rhinitis
- Preliminary Final Report
- Paradigm PPS a potential in the treatment of viral arthritis
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals